• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Amarin Corporation plc (Amendment)

    2/21/23 6:02:43 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRN alert in real time by email
    SC 13D/A 1 ny20006859x25_sc13da.htm SC 13D/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549
     
    SCHEDULE 13D

    Under the Securities Exchange Act of 1934
    (Amendment No. 10)*


    Amarin Corporation plc
    (Name of Issuer)
     
    Ordinary Shares, par value 50 pence per share
    (Title of Class of Securities)
     
    023111206
    (CUSIP Number)
     
    Mark DiPaolo
    Senior Partner, General Counsel
    Sarissa Capital Management LP
    660 Steamboat Road
    Greenwich, CT 06830
    203-302-2330
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     
    February 17, 2023
    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐
     
    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
     
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 023111206
    Page 2 of 4 Pages
    SCHEDULE 13D


    This Amendment No. 10 to Schedule 13D (“Amendment No. 10”) relates to American Depositary Shares (“ADS(s)”), each ADS representing one ordinary share, par value 50 pence per share (the “Ordinary Shares”), issued by Amarin Corporation plc, a company incorporated under the laws of England and Wales (the “Issuer”), and amends the initial statement on Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on January 24, 2022 (the “Initial Schedule 13D”), as amended by Amendment No. 1 to Schedule 13D filed on June 3, 2022, Amendment No. 2 to Schedule 13D filed on June 16, 2022, Amendment No. 3 to Schedule 13D filed on October 11, 2022, Amendment No. 4 to Schedule 13D filed on January 11, 2023, Amendment No. 5 to Schedule 13D filed on January 19, 2023, Amendment No. 6 to Schedule 13D filed on February 8, 2023, Amendment No. 7 to Schedule 13D filed on February 10, 2023, Amendment No. 8 to Schedule 13D filed on February 14, 2023, and Amendment No. 9 to Schedule 13D filed on February 15, 2023 (the Initial Schedule 13D as so amended, the “Schedule 13D”). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.
     
    This Amendment No. 10 is being filed to amend Item 4 and Item 7 as follows:
     
    Item 4.  Purpose of Transaction. Item 4 of the Schedule 13D is hereby amended to include the following:
     
    On February 17, 2023, Sarissa Capital issued the press release attached as Exhibit 13 hereto.
     
    Item 7.  Material to Be Filed as Exhibits. Item 7 of the Schedule 13D is hereby amended to include the following:
     
    Exhibit 13 – Press Release, February 17, 2023
     

    CUSIP No. 023111206
    Page 3 of 4 Pages
    SCHEDULE 13D
     
    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: February 21, 2023

    SARISSA CAPITAL MANAGEMENT LP
     
         
         
    By:
    /s/ Mark DiPaolo
     
     
    Name: Mark DiPaolo
     
     
    Title: Senior Partner, General Counsel
     
         
         
    /s/ Alexander J. Denner
     
    Alexander J. Denner
     
         
    /s/ Louis Sterling III
     
    Louis Sterling III
     

    CUSIP No. 023111206
    Page 4 of 4 Pages
    SCHEDULE 13D

    INDEX TO EXHIBITS

    Exhibit 13 – Press Release, February 17, 2023




    Get the next $AMRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMRN

    DatePrice TargetRatingAnalyst
    11/20/2023Underweight
    JP Morgan
    10/25/2023$3.00 → $1.00Buy → Hold
    Jefferies
    1/6/2023$1.30 → $3.00Hold → Buy
    Jefferies
    5/6/2022Neutral → Underweight
    JP Morgan
    5/5/2022$10.00 → $3.00Outperform → Mkt Perform
    SVB Leerink
    5/5/2022$10.00 → $3.00Buy → Neutral
    H.C. Wainwright
    5/4/2022Outperform → Market Perform
    Northland Capital
    2/16/2022$11.00 → $10.00Outperform
    SVB Leerink
    More analyst ratings